Metagenomi Therapeutics (MGX) Operating Leases (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Operating Leases data on file, last reported at $33.1 million in Q1 2026.

• Operating Leases for Q1 2026 came in at $33.1 million, down 14.81% year-over-year; the trailing twelve-month figure through Mar 2026 was $33.1 million (down 14.81% YoY), and the FY2025 annual result was $34.6 million, down 13.82% from the prior year.
• Operating Leases eased to $33.1 million in Q1 2026 per MGX's latest filing, from $34.6 million in the prior quarter.
• Over five years, Operating Leases peaked at $44.8 million in Q4 2023 and troughed at $33.1 million in Q1 2026.
• A 4-year average of $39.3 million and a median of $39.5 million in 2024 frame the typical range for Operating Leases.
• The sharpest annual moves came in 2024 and 2026: Operating Leases slipped 10.3% in 2024, then slipped 14.81% in 2026.
• A 4-year view of Operating Leases shows it stood at $44.8 million in 2023, then slipped by 10.3% to $40.2 million in 2024, then dropped by 13.82% to $34.6 million in 2025, then decreased by 4.48% to $33.1 million in 2026.
• Business Quant data shows MGX's Operating Leases at $33.1 million in Q1 2026, $34.6 million in Q4 2025, and $36.1 million in Q3 2025.